Lineage Cell TherapeuticsvsMerck & Company

LCTX and MRK stock compared: price, dividend, valuation and results, from SEC filings.

LCTX

Lineage Cell Therapeutics, Inc.

$0.77

Value $192M

-6.10%
LCTX's page

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

Lineage Cell Therapeutics (LCTX) has a market value of $192M and Merck & Company (MRK) $331B. Over the last year, with dividends, LCTX moved -55.0% and MRK +44.8%. Dividend yield: LCTX none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LCTX$192M

    MRK$331B

    MRK is 1,719 times LCTX

  • Revenue, 12 months

    LCTX$11M

    MRK$67.4B

    MRK is 6,218 times LCTX

  • Net income, 12 months

    LCTX$1.8M

    MRK$2.5B

    MRK is 1,399 times LCTX

  • Operating margin

    LCTX-280.3%

    MRK–

  • ROIC

    LCTX-48.3%

    MRK3.9%

    52.2 points apart

  • P/E

    LCTX–

    MRK134.8

  • Dividend yield

    LCTX0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    LCTX-66.4%

    MRK+93.0%

    159.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LCTX-66.4%

MRK+93.0%

10020020222023202420252026
Returns by period
PeriodLCTXWith dividendsMRKWith dividends
1 year since November 19, 2025-55.0%Price -55.0%+44.8%Price +40.7%
3 years since November 20, 2023-28.0%-10.4% a yearPrice -28.0%+42.7%+12.6% a yearPrice +30.2%
5 years since November 19, 2021-66.4%-19.6% a yearPrice -66.4%+93.0%+14.1% a yearPrice +65.7%
10 years since November 22, 2016-76.2%-13.4% a yearPrice -76.2%+208.2%+11.9% a yearPrice +127.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LCTXLineage Cell TherapeuticsMRKMerck & Company

Valuation

LCTXMRK
Valuation
Price$0.77$133.72
Market value$192M$331B
Enterprise value (EV)$147M$375B
P/E–134.8
P/E, 5-year median–14.8
P/B2.97.4
EV/EBIT–78.7
Free cash flow yield–4.5%

Results and growth

LCTXMRK
Results and growth
Revenue, 12 months$11M$67.4B
Net income, 12 months$1.8M$2.5B
Free cash flow, 12 months-$26M$14.7B
Earnings per share, 12 months-$0.09$0.98
Revenue growth, year on year53.2%1.3%
Revenue growth a year, past+51.5%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

LCTXMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin-280.3%–
Net margin16.2%3.6%
ROIC-48.3%3.9%
ROE3.5%5.2%

Balance sheet

LCTXMRK
Balance sheet
Cash$45M$9.7B
Total debt$2.0M$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

LCTXMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LCTX or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Lineage Cell Therapeutics or Merck & Company?

By market value, Merck & Company ($331B) is about 1,719.5 times Lineage Cell Therapeutics ($192M), at today's prices.

How did LCTX and MRK stock do over the last 10 years?

Since November 22, 2016, LCTX's price moved -76.2% and MRK's +127.1%. With dividends: LCTX -76.2% (-13.4% a year), MRK +208.2% (+11.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, LCTX or MRK?

The dividend yield at today's price is none for Lineage Cell Therapeutics and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Lineage Cell Therapeutics or Merck & Company?

Over the last twelve months, the net margin was 16.2% for Lineage Cell Therapeutics and 3.6% for Merck & Company, and the operating margin -280.3% and –. Revenue was $11M and $67.4B.

Which is the better investment, Lineage Cell Therapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.